These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15871703)

  • 1. Concordance of the hormone receptors and correlation of HER-2/neu overexpression of the metachronous cancers of contralateral breasts.
    Stark A; Lu M; Mackowiak P; Linden M
    Breast J; 2005; 11(3):183-7. PubMed ID: 15871703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
    Elledge RM; Green S; Ciocca D; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; O'Sullivan J; Martino S; Osborne CK
    Clin Cancer Res; 1998 Jan; 4(1):7-12. PubMed ID: 9516946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women.
    Gammon MD; Hibshoosh H; Terry MB; Bose S; Schoenberg JB; Brinton LA; Bernstein JL; Thompson WD
    Cancer Epidemiol Biomarkers Prev; 1999 May; 8(5):413-9. PubMed ID: 10350436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implication of HER-2/neu overexpression for the efficacy of oral fluoropyrimidine-based adjuvant chemotherapy in the patients with estrogen receptor negative breast cancer after surgery.
    Nio Y; Itakura M; Omori H; Koike M; Hashimoto K; Yano S; Toga T; Higami T
    Anticancer Res; 2003; 23(1B):745-53. PubMed ID: 12680178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.
    Dowsett M; Harper-Wynne C; Boeddinghaus I; Salter J; Hills M; Dixon M; Ebbs S; Gui G; Sacks N; Smith I
    Cancer Res; 2001 Dec; 61(23):8452-8. PubMed ID: 11731427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Her-2/neu oncogene expression in Puerto Rican females with breast cancer.
    Peredo R; Sastre G; Serrano J; Hunter Mellado R
    Cell Mol Biol (Noisy-le-grand); 2001 Sep; 47(6):1025-32. PubMed ID: 11785652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients.
    Shackney SE; Pollice AA; Smith CA; Janocko LE; Sweeney L; Brown KA; Singh SG; Gu L; Yakulis R; Lucke JF
    Clin Cancer Res; 1998 Apr; 4(4):913-28. PubMed ID: 9563885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
    Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
    J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Her-2/neu gene overexpression in breast carcinoma and its association with clinicopathological characteristics of the disease.
    Ahmad A; Bano U; Gondal M; Khan A
    J Coll Physicians Surg Pak; 2009 May; 19(5):297-9. PubMed ID: 19409162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
    Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
    J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Correlation of Her-2 overexpression with endocrine status and response to tamoxifen treatment in patients with breast cancer].
    Zhang J; Zhang JH; Liu Y; Hao XM; Fang ZX; Li SL
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(46):3268-71. PubMed ID: 18396622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen.
    Muss HB; Bunn JY; Crocker A; Plaut K; Koh J; Heintz N; Rincon M; Weaver DL; Tam D; Beatty B; Kaufman P; Donovan M; Verbel D; Weiss L
    Breast J; 2007; 13(4):337-45. PubMed ID: 17593037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.
    Lipton A; Leitzel K; Ali SM; Demers L; Harvey HA; Chaudri-Ross HA; Evans D; Lang R; Hackl W; Hamer P; Carney W
    Cancer; 2005 Jul; 104(2):257-63. PubMed ID: 15952182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of steroid receptors and HER 2/neu in breast cancer biopsies of women living in Puerto Rico.
    Colón E; Reyes JS; González Keelan C; Climent-Peris C
    P R Health Sci J; 2002 Dec; 21(4):299-303. PubMed ID: 12572236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the relationship between human epidermal growth factor receptor-2/neu (c-erbB-2) amplification and pathologic grading in patients with breast cancer.
    Homaei-Shandiz F; Ghavam-Nassiri MR; Sharifi N; Homaei-Shandiz AH; Taghizadeh-Kermani A; Torshizi SA; Ghafarzadegan K
    Saudi Med J; 2006 Dec; 27(12):1810-4. PubMed ID: 17143354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women.
    Nichols HB; Trentham-Dietz A; Love RR; Hampton JM; Hoang Anh PT; Allred DC; Mohsin SK; Newcomb PA
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):41-7. PubMed ID: 15668474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
    Prati R; Apple SK; He J; Gornbein JA; Chang HR
    Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.